Ramelteon
- Generic Name
- Ramelteon
- Brand Names
- Rozerem
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 196597-26-9
- Unique Ingredient Identifier
- 901AS54I69
- Background
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
- Indication
用于失眠症，特别适用于治疗难以入睡型失眠症。
- Associated Conditions
- Insomnia
Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia
- Conditions
- InsomniaSpinal Cord InjuryTetraplegiaSleep Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 12
- Registration Number
- NCT00507546
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Lehigh Valley Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00502320
- Locations
- 🇺🇸
Lehigh Valley Hospital, Department of Psychiatry, Allentown, Pennsylvania, United States
Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 110
- Registration Number
- NCT00492011
Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
- Conditions
- Chronic Insomnia
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2010-07-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 135
- Registration Number
- NCT00492232
Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2010-11-11
- Target Recruit Count
- 4
- Registration Number
- NCT00462254
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 552
- Registration Number
- NCT00414102
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Charlottesville Neuroscience
- Target Recruit Count
- 4
- Registration Number
- NCT00391755
- Locations
- 🇺🇸
Patricia Shipley, MD, Charlottesville, Virginia, United States
Treating Chronic Insomnia in Breast Cancer Patients
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 16
- Registration Number
- NCT00337272
- Locations
- 🇺🇸
Augusta Oncology Associates, PC, Augusta, Georgia, United States
🇺🇸Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 74
- Registration Number
- NCT00325728
Effects of Ramelteon on Driving Ability
- Conditions
- Insomnia
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2007-04-25
- Lead Sponsor
- Utrecht Institute for Pharmaceutical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00319215
- Locations
- 🇳🇱
Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.